Cala Trio is a Rising Standard of Care for the Treatment of Essential Tremor through Clinical Research and Industry Guidelines

BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, a bioelectronic medicine company developing wearable therapies for chronic disease, announces two validating pieces of news for the non-invasive prescription therapy for essential tremor (ET), Cala Trio™. Real-world evidence of a Veteran Affairs (VA) patient population presented at The International Parkinson and Movement Disorder Society (MDS) 2021 virtual congress on September 15 showcases Cala Trio as dramatically decreasing tremor movement and severity in patients with ET. This novel research comes on the heels of the International Essential Tremor Foundation (IETF) guidelines outlining the device in a new, recommended therapeutic option for patients with ET.